Radioiummunotherapy after chemotherapy found safe and effective for follicular non-hodgkin lymphoma patients
Radioimmunotherapy with the radioactive drug yttrium-90 (90Y) ibritumombab tiuxetan, following chemotherapy with fludarabine and mitoxantrone, is feasible, well tolerated, and effective in patients with follicular non-Hodgkin lymphoma (NHL). These are the conclusions of authors of an Article published early online and in the April Edition of The Lancet Oncology.
Follicular lymphoma accounts for around 30% of all newly diagnosed NHLs, and is the most common form of lymphoma in the USA and Europe. The findings of various trials have shown that combination of a chemotherapy regimen with rituximab (a non-radioactive targeted treatment for B-cell lymphomas) significantly increased progression-free-survival compared with the same chemotherapy regimen alone.
The researchers wanted to see if these benefits could be improved if, instead of rituximab, 90Y-ibritumombab tiuxetan was used-which, as with rituximab, is able to target B-cell lymphomas by attaching to a surface protein on those cells. Once attached, β-radiation from the radioactive yttrium-90 attacks and kills these highly-radiation sensitive lymphoma cells.
Professor Pier Luigi Zinzani, at the Institute of Haematology and Oncology 'L & A Seràgnoli', University of Bologna, Italy, and colleagues did a study of 61 patients across 13 Italian institutions. All received six cycles of oral fludarabine and intravenous mitoxantrone; and 57 of these-43 with complete response (CR) and 14 with partial response (PR)-were deemed eligible for subsequent 90Y-ibritumombab tiuxetan. Then of the 14 PR patients, 12 achieved CR after 90Y-ibritumombab tiuxetan treatment; thus overall 55 of the 57 patients achieved complete response after the combined treatment regimen.
Further, with a median follow-up of 30 months, 3-year progression-free survival was estimated at 76%, and 3-year overall survival 100%. 36 of 57 patients had grade 3 or 4 haemotological toxic effects.
The authors conclude: "This study has established the feasibility, tolerability, and efficacy of sequential treatment with six cycles of fludarabine and mitoxantrone chemotherapy followed by 90Y-ibritumombab tiuxetan as a front-line treatment for untreated patients with follicular NHL. In particular, the data represent the first evidence of a role of 90Y-ibritumombab tiuxetan after a fludarabine-containing regimen in the treatment of follicular NHL."
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.